Correction: The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 10 3 2019
medline: 10 3 2019
entrez: 10 3 2019
Statut: ppublish

Résumé

Following the publication of this article, the authors noted that Dr Laura Fancello was not listed among the authors. The corrected author list is given below. Additionally, the following was not included in the author contribution statement: 'L.F. analyzed RNA sequencing data'.

Identifiants

DOI: 10.1038/s41375-019-0424-x PMID: 30850735 PMC: PMC6756081
pubmed: 30850735
doi: 10.1038/s41375-019-0424-x
pii: 10.1038/s41375-019-0424-x
pmc: PMC6756081
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

1055-1062

Commentaires et corrections

Type : ErratumFor

Auteurs

Kim R Kampen (KR)

Department of Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Sergey O Sulima (SO)

Department of Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Benno Verbelen (B)

Department of Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Tiziana Girardi (T)

Department of Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Stijn Vereecke (S)

Department of Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.
ORCID: 0000-0001-8414-8907

Laura Fancello (L)

Department of Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Gianmarco Rinaldi (G)

Laboratory of Cellular Metabolism and Metabolic Regulation, Center for Cancer Biology, VIB, Leuven, Belgium.
Department of Oncology, Laboratory of Cellular Metabolism and Metabolic Regulation, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Jelle Verbeeck (J)

Department of Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Joyce Op de Beeck (J)

Department of Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Anne Uyttebroeck (A)

Department of Pediatric Oncology & Hematology, University Hospitals Leuven, Leuven, Belgium.

Jules P P Meijerink (JPP)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Anthony V Moorman (AV)

Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.

Christine J Harrison (CJ)

Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.

Pieter Spincemaille (P)

Department of Gastroenterology-Hepatology and Metabolic Center, University Hospitals Leuven, Leuven, Belgium.

Jan Cools (J)

Laboratory of Molecular Biology of Leukemia, Center for Human Genetics, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.
Laboratory of Molecular Biology of Leukemia, Center for Cancer Biology, VIB, Leuven, Belgium.

David Cassiman (D)

Department of Gastroenterology-Hepatology and Metabolic Center, University Hospitals Leuven, Leuven, Belgium.

Sarah-Maria Fendt (SM)

Laboratory of Cellular Metabolism and Metabolic Regulation, Center for Cancer Biology, VIB, Leuven, Belgium.
Department of Oncology, Laboratory of Cellular Metabolism and Metabolic Regulation, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Pieter Vermeersch (P)

Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.

Kim De Keersmaecker (K)

Department of Oncology, Laboratory for Disease Mechanisms in Cancer, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium. kim.dekeersmaecker@kuleuven.be.

Classifications MeSH